Davenport & Co’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$86.7M Buy
1,098,548
+12,649
+1% +$1.02M 0.43% 79
2026
Q1
$93.8M Buy
1,085,899
+24,457
+2% +$2.34M 0.51% 66
2025
Q4
$102M Sell
1,061,442
-5,741
-0.5% -$558K 0.54% 57
2025
Q3
$101M Sell
1,067,183
-14,265
-1% -$1.31M 0.54% 62
2025
Q2
$93.9M Sell
1,081,448
-13,083
-1% -$1.11M 0.51% 70
2025
Q1
$97.7M Buy
1,094,531
+32,869
+3% +$2.94M 0.57% 61
2024
Q4
$84.7M Sell
1,061,662
-33,468
-3% -$2.9M 0.48% 73
2024
Q3
$98.4M Sell
1,095,130
-15,389
-1% -$1.29M 0.56% 61
2024
Q2
$87.6M Sell
1,110,519
-22,937
-2% -$1.88M 0.53% 65
2024
Q1
$98.7M Sell
1,133,456
-30,149
-3% -$2.57M 0.61% 53
2023
Q4
$96M Sell
1,163,605
-86,442
-7% -$6.59M 0.65% 51
2023
Q3
$98.1M Sell
1,250,047
-9,605
-0.8% -$804K 0.74% 39
2023
Q2
$111M Sell
1,259,652
-98,301
-7% -$8.46M 0.81% 33
2023
Q1
$109M Buy
1,357,953
+25,036
+2% +$2.04M 0.85% 33
2022
Q4
$104M Buy
1,332,917
+120,940
+10% +$9.8M 0.85% 27
2022
Q3
$98.4M Sell
1,211,977
-442,932
-27% -$39.8M 0.86% 28
2022
Q2
$149M Buy
1,654,909
+151,596
+10% +$15.4M 1.22% 12
2022
Q1
$167M Buy
1,503,313
+208,121
+16% +$22M 1.14% 16
2021
Q4
$134M Buy
1,295,192
+654
+0.1% +$75.7K 0.88% 27
2021
Q3
$162M Buy
1,294,538
+53,929
+4% +$6.98M 1.15% 19
2021
Q2
$154M Buy
1,240,609
+110,782
+10% +$13.9M 1.18% 19
2021
Q1
$133M Sell
1,129,827
-14,136
-1% -$1.66M 1.25% 17
2020
Q4
$134M Buy
1,143,963
+1,693
+0.1% +$186K 1.32% 15
2020
Q3
$119M Sell
1,142,270
-23,028
-2% -$2.31M 1.33% 16
2020
Q2
$107M Buy
1,165,298
+447,975
+62% +$43M 1.3% 21
2020
Q1
$64.7M Buy
717,323
+169,745
+31% +$18.1M 0.93% 30
2019
Q4
$62.1M Buy
547,578
+21,765
+4% +$2.39M 0.66% 48
2019
Q3
$52.6M Sell
525,813
-6,119
-1% -$638K 0.63% 55
2019
Q2
$51.8M Buy
531,932
+2,202
+0.4% +$201K 0.62% 59
2019
Q1
$48.2M Sell
529,730
-1,340
-0.3% -$120K 0.6% 61
2018
Q4
$48.3M Sell
531,070
-2,205
-0.4% -$206K 0.66% 53
2018
Q3
$52.5M Buy
533,275
+8,835
+2% +$817K 0.61% 63
2018
Q2
$44.9M Sell
524,440
-7,776
-1% -$650K 0.55% 74
2018
Q1
$42.7M Buy
532,216
+12,200
+2% +$1.01M 0.53% 82
2017
Q4
$42M Buy
520,016
+512,013
+6,398% +$41M 0.5% 85
2017
Q3
$622K Sell
8,003
-331
-4% -$27.5K 0.01% 395
2017
Q2
$740K Sell
8,334
-4,450
-35% -$375K 0.01% 348
2017
Q1
$911K Sell
12,784
-474
-4% -$37K 0.01% 303
2016
Q4
$944K Sell
13,258
-793
-6% -$62.3K 0.01% 296
2016
Q3
$1.21M Buy
14,051
+2,815
+25% +$245K 0.02% 263
2016
Q2
$975K Buy
11,236
+1,697
+18% +$137K 0.01% 293
2016
Q1
$715K Sell
9,539
-197
-2% -$14.8K 0.01% 328
2015
Q4
$749K Sell
9,736
-1,240
-11% -$93.3K 0.01% 317
2015
Q3
$735K Buy
10,976
+401
+4% +$29.5K 0.01% 318
2015
Q2
$784K Sell
10,575
-2,140
-17% -$164K 0.01% 316
2015
Q1
$992K Buy
12,715
+7
+0.1% +$531 0.02% 300
2014
Q4
$918K Sell
12,708
-1,399
-10% -$97.2K 0.01% 292
2014
Q3
$874K Sell
14,107
-497
-3% -$31.6K 0.02% 293
2014
Q2
$931K Sell
14,604
-347
-2% -$21.1K 0.02% 283
2014
Q1
$920K Sell
14,951
-198
-1% -$11.5K 0.02% 275
2013
Q4
$869K Sell
15,149
-1,154
-7% -$65.4K 0.02% 279
2013
Q3
$868K Buy
16,303
+158
+1% +$8.5K 0.02% 263
2013
Q2
$831K Buy
+16,145
New +$798K 0.02% 252

Other funds holding MDT

Davenport & Co's MDT Position: Q2 2026 in Review

Davenport & Co increased its Medtronic (MDT) stake by 1.2% in Q2 2026, buying an estimated $1.02M and bringing the position to 1,098,548 shares worth $86.7M. The position accounts for 0.43% of the portfolio, ranked #79.

Davenport & Co first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $167M in Q1 2022. 372 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Davenport & Co held 1,098,548 shares of Medtronic worth $86.7M as of Q2 2026.
  • Davenport & Co bought 12,649 Medtronic shares in Q2 2026, an estimated $1.02M.
  • Medtronic made up 0.43% of Davenport & Co's portfolio in Q2 2026, its #79 holding.
  • Davenport & Co first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • Davenport & Co's Medtronic position peaked at $167M in Q1 2022.
  • 372 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.